Semaglutide for Liver Fat: What the MASH Data Shows
MASH & Liver Disease
62.9%
Percentage of patients who achieved MASH resolution without worsening fibrosis on semaglutide 2.4 mg in the ESSENCE phase 3 trial, versus 34.3% on placebo.
Sanyal et al., NEJM, 2025
Sanyal et al., NEJM, 2025
View as imageIn June 2025, the New England Journal of Medicine published the ESSENCE trial results: semaglutide 2.4 mg resolved metabolic dysfunction-associated steatohepatitis (MASH) in 62.9% of patients with moderate-to-advanced liver fibrosis, compared to 34.3% on placebo.[1] Two months later, the FDA approved semaglutide as the first GLP-1 receptor agonist for MASH with liver fibrosis. For a disease that affects an estimated 6-8% of the global adult population and until recently had zero approved pharmacotherapies, these numbers represent a turning point. But the data is more layered than headlines suggest. Semaglutide for liver fat reduction involves mechanisms beyond weight loss, trial results that differ by fibrosis stage, and unanswered questions about long-term liver outcomes. This article examines what 18 studies reveal about where the evidence stands.
For a broader overview of the disease itself, including prevalence, staging, and the renaming from NASH to MASH, see MASH (Formerly NASH): The Liver Disease Epidemic and Peptide Solutions.
Key Takeaways
- Semaglutide 2.4 mg resolved MASH without worsening fibrosis in 62.9% of patients versus 34.3% on placebo in the 1,197-patient ESSENCE phase 3 trial (Sanyal et al., NEJM 2025)
- The earlier phase 2 trial showed a dose-response: NASH resolution occurred in 40% (0.1 mg), 36% (0.2 mg), and 59% (0.4 mg daily) versus 17% on placebo (Newsome et al., NEJM 2021)
- Fibrosis improvement occurred in 36.8% on semaglutide versus 22.4% on placebo in the ESSENCE trial, a statistically significant but more modest effect than MASH resolution
- Real-world data from a 52-week study in type 2 diabetes patients showed semaglutide reduced liver stiffness measurements and improved hepatic steatosis index scores (Volpe et al., 2022)
- In patients with MASH-related cirrhosis (F4 fibrosis), a separate phase 2 trial found no significant improvement in fibrosis, suggesting semaglutide works better in earlier disease stages
- The FDA approved semaglutide (Wegovy) for MASH with moderate-to-advanced fibrosis in August 2025, excluding patients with cirrhosis
What Is MASH and Why Liver Fat Matters
MASH, previously called nonalcoholic steatohepatitis or NASH, is a progressive liver disease driven by metabolic dysfunction. It begins with excess fat accumulation in the liver (steatosis), progresses to inflammation and hepatocyte injury (steatohepatitis), and can advance through stages of fibrosis toward cirrhosis, liver failure, and hepatocellular carcinoma. The nomenclature changed in 2023 when a global consortium replaced "nonalcoholic" with "metabolic dysfunction-associated," reflecting the disease's metabolic origins rather than defining it by what it is not.[2]
The clinical challenge is two-fold. First, MASH is largely silent until advanced fibrosis or cirrhosis develops. Most patients have no symptoms. Second, until resmetirom received FDA approval in March 2024 and semaglutide followed in August 2025, clinicians had no approved drugs specifically targeting MASH. Treatment consisted of lifestyle interventions and managing comorbidities like diabetes and obesity. For a complete look at every peptide-based therapy in the MASH pipeline, see Every Peptide Being Studied for MASH: A Pipeline Overview.
The fibrosis stage at diagnosis is the strongest predictor of liver-related mortality. Patients with stage F3 (bridging fibrosis) or F4 (cirrhosis) face the highest risk of decompensation and death. This is why clinical trials in MASH use histological endpoints rather than just measuring liver fat: the regulatory bar requires demonstrating that a drug resolves steatohepatitis, improves fibrosis, or both.
How Semaglutide Acts on the Liver
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes and obesity. Its primary mechanism involves mimicking the incretin hormone GLP-1, slowing gastric emptying, reducing appetite through hypothalamic signaling, and enhancing insulin secretion. But its effects on the liver extend beyond the indirect benefits of weight loss and improved glycemic control.
A 2025 study published in Nature Medicine by Jara et al. examined the molecular pathways through which semaglutide modifies liver pathology in MASH.[3] In preclinical models, semaglutide reduced hepatic expression of genes involved in fibrogenesis, inflammatory signaling, and stellate cell activation. It improved histological markers of both inflammation and fibrosis. Semaglutide also modulated de novo lipogenesis pathways, reducing the liver's production of new fat from non-lipid substrates.
At the cellular level, research by Hu et al. (2025) demonstrated that semaglutide reduces hepatocyte steatosis through the IRE1a-XBP1-C/EBPa signaling axis, downregulating macrophage-driven inflammatory responses in co-culture systems.[4] This suggests direct hepatoprotective action in addition to systemic metabolic improvement.
GLP-1 receptors have been identified on hepatocytes and hepatic stellate cells, though their density is lower than in pancreatic beta cells. Whether semaglutide's liver benefits come primarily from direct receptor activation in hepatic tissue or from systemic metabolic correction remains an active area of investigation.[5] A 2023 review by Newsome et al. in the Journal of Hepatology concluded that both direct and indirect mechanisms likely contribute, with weight loss accounting for a substantial but incomplete portion of the histological improvement.[6]
For context on how semaglutide's metabolic effects extend to cardiovascular outcomes, see GLP-1 Drugs and Heart Disease: What the Cardiovascular Trials Show. Its effects on blood sugar control are covered in Semaglutide A1C Reduction: What the Diabetes Trials Show.
The Phase 2 Trial: First Proof in Biopsy-Confirmed NASH
The first randomized controlled trial of semaglutide in biopsy-confirmed NASH was published in the New England Journal of Medicine in 2021.[7] Newsome et al. enrolled 320 patients with NASH and liver fibrosis stage F1 through F3 in a 72-week, double-blind, dose-ranging trial. Patients received once-daily subcutaneous semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg, or placebo.
The results established a clear dose-response pattern for NASH resolution:
- 0.1 mg: 40% achieved NASH resolution (vs. 17% placebo)
- 0.2 mg: 36% achieved NASH resolution
- 0.4 mg: 59% achieved NASH resolution (P<0.001 vs. placebo)
Weight loss followed the same gradient: the 0.4 mg group lost a mean of 13% body weight versus 1% on placebo. The trial also showed improvements in liver enzymes (ALT, AST) and inflammatory markers across all semaglutide doses.
The critical limitation was fibrosis. Improvement in fibrosis stage occurred in 43% of the 0.4 mg group versus 33% on placebo, a difference that was not statistically significant (P=0.48). This raised a question that the ESSENCE trial would later address: could semaglutide improve fibrosis with a larger sample, different dosing, or longer treatment duration?
Barritt et al. (2022) contextualized this result in a review of GLP-1 receptor agonists for NASH, noting that fibrosis improvement typically lags behind inflammation resolution by months or years, and that 72 weeks may be insufficient to capture the full fibrotic response to treatment.[8]
The ESSENCE Trial: Phase 3 Confirmation
The ESSENCE trial (NCT04822181) is the definitive study that led to semaglutide's FDA approval for MASH. Published in the NEJM in 2025 by Sanyal et al., it enrolled 1,197 patients with biopsy-confirmed MASH and fibrosis stage F2 or F3 in a 2:1 randomization to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks.[1]
The published results represent a planned interim analysis at 72 weeks involving the first 800 patients. Both co-primary endpoints were met:
MASH resolution without worsening fibrosis: 62.9% semaglutide vs. 34.3% placebo (estimated difference 28.7 percentage points; 95% CI, 21.1-36.2; P<0.001).
Fibrosis improvement without worsening MASH: 36.8% semaglutide vs. 22.4% placebo (estimated difference 14.4 percentage points; 95% CI, 7.5-21.3; P<0.001).
The combined endpoint of both MASH resolution and fibrosis improvement was achieved in 32.7% of semaglutide patients versus 16.1% on placebo (P<0.001). Mean body weight change was -10.5% with semaglutide versus -2.0% with placebo.
Three aspects distinguish the ESSENCE trial from the phase 2 study. First, it used the weekly 2.4 mg dose (the same as Wegovy for obesity) rather than daily dosing. Second, it restricted enrollment to F2 and F3 fibrosis, selecting patients at highest risk of progression. Third, and most critically, it achieved a statistically significant fibrosis improvement, the endpoint the phase 2 trial missed.
The full 240-week results from ESSENCE part 2 are still pending. These will assess hard clinical outcomes: death, liver transplant, progression to cirrhosis, and liver-related clinical events. Histological surrogate endpoints, while meaningful, remain surrogates. Whether resolving MASH on biopsy translates to preventing liver failure and death over years of treatment requires data that does not yet exist.
The Cirrhosis Question
A separate phase 2 trial published in The Lancet Gastroenterology & Hepatology by Loomba et al. (2023) tested semaglutide 2.4 mg weekly in patients with NASH-related compensated cirrhosis (F4 fibrosis).[9] This is the population with the most advanced disease and highest unmet need.
The results were sobering. While semaglutide improved body weight and cardiometabolic parameters in these patients, it did not produce statistically significant improvement in liver fibrosis. The study enrolled a smaller number of patients and was not powered for definitive fibrosis conclusions, but the signal was clearly weaker than in earlier-stage disease.
This finding directly shaped the FDA's approval scope. Semaglutide was approved for MASH with moderate-to-advanced fibrosis (F2-F3), explicitly excluding cirrhosis. The biological rationale aligns with what hepatologists have long observed: once fibrosis progresses to cirrhosis, the degree of architectural distortion and cross-linked collagen deposition makes reversal substantially more difficult.
For patients with established cirrhosis, the MASH treatment pipeline includes other candidates. See Survodutide: The Liver-Targeted Dual Agonist for MASH for data on the glucagon/GLP-1 dual agonist being tested across fibrosis stages.
Liver Fat Reduction: What Imaging Studies Show
While histological endpoints from biopsies are the gold standard for MASH trials, imaging studies provide complementary data on liver fat content changes with semaglutide treatment.
Dusilova et al. (2024) measured liver fat content using MRI-based proton density fat fraction (PDFF) in obese patients with metabolic-associated steatotic liver disease (MASLD).[10] After semaglutide treatment, liver fat decreased by approximately one-third from baseline. This magnitude of reduction is consistent with the SLIM LIVER study, which used similar imaging techniques to quantify hepatic fat changes.[11]
Golub et al. (2025) used serial cardiac CT scans in the STOP trial to assess semaglutide's impact on liver fat in type 2 diabetes patients.[12] Semaglutide produced significant reductions in hepatic steatosis compared to placebo, measurable on CT imaging that was originally designed for cardiac assessment. This incidental finding underscores how consistently semaglutide reduces liver fat across different study designs and patient populations.
Real-world data adds another dimension. Volpe et al. (2022) followed 32 patients with type 2 diabetes and fatty liver disease on once-weekly semaglutide for 52 weeks in a prospective clinical practice setting.[13] They observed improvements in hepatic steatosis index, fibrosis-4 score, and liver stiffness measurements alongside reductions in liver enzymes. These real-world improvements, achieved without the strict selection criteria of randomized trials, suggest the effects translate beyond controlled research settings.
Liver Enzyme and Biomarker Changes
Before biopsy-based trials confirmed MASH resolution, earlier studies documented semaglutide's effects on liver-related biomarkers. Newsome et al. (2019) published a pooled analysis of semaglutide's effects on liver enzymes and inflammatory markers from clinical trials in type 2 diabetes and obesity.[14] Semaglutide significantly reduced alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hsCRP) compared to placebo, suggesting anti-inflammatory and hepatoprotective effects even in populations not selected for liver disease.
Carretero-Gomez et al. (2023) confirmed these findings in a study of semaglutide's effects on fatty liver disease biomarkers in patients with both diabetes and obesity.[15] ALT normalization occurred in a majority of patients, and improvements correlated with but were not entirely explained by weight loss.
These biomarker studies were instrumental in building the mechanistic case for the ESSENCE trial. They suggested that semaglutide was not merely reducing liver fat through caloric deficit but was modifying the inflammatory milieu that drives progression from simple steatosis to steatohepatitis and fibrosis.
FDA Approval and Updated Clinical Guidelines
On August 15, 2025, the FDA approved semaglutide (marketed as Wegovy) for the treatment of adults with MASH and moderate-to-advanced liver fibrosis (stages F2 and F3), excluding cirrhosis. This made semaglutide the second drug ever approved for MASH (after resmetirom in March 2024) and the first GLP-1 receptor agonist approved for this indication.
The AASLD updated its Practice Guidance in November 2025 to incorporate semaglutide into the MASH treatment algorithm.[2] The guidance provides recommendations on patient selection (biopsy-confirmed MASH with F2-F3 fibrosis), consideration of comorbidities like obesity and type 2 diabetes that may favor semaglutide over resmetirom, and monitoring protocols for treatment efficacy and safety.
A key consideration in clinical practice is that many patients with MASH also have obesity and/or type 2 diabetes. Semaglutide treats all three conditions simultaneously. Resmetirom, by contrast, targets the liver specifically through thyroid hormone receptor beta activation. For patients whose primary disease burden is hepatic, resmetirom may be preferred. For patients with significant metabolic comorbidity, semaglutide addresses multiple conditions with a single agent.
How Semaglutide Compares to Other MASH Peptide Therapies
Semaglutide is not the only incretin-based therapy under investigation for MASH. The landscape includes dual and triple agonists that may offer enhanced liver-specific effects.
Tirzepatide, a dual GIP/GLP-1 receptor agonist, was tested in the SYNERGY-NASH trial. Loomba et al. (2024) reported in the NEJM that tirzepatide resolved MASH without worsening fibrosis in up to 74% of patients at the highest dose, compared to 13% on placebo.[16] These rates numerically exceed semaglutide's, though cross-trial comparisons have significant limitations due to differences in patient populations, fibrosis stage distributions, and biopsy reading methodologies. For a deeper examination of these data, see Tirzepatide and Liver Disease: The Metabolic Liver Connection.
Survodutide, a dual GLP-1/glucagon receptor agonist, was evaluated in a phase 2 trial by Sanyal et al. (2024) in the NEJM.[17] The glucagon component may provide additional liver-specific benefit by directly stimulating hepatic fat oxidation. Phase 3 results are pending. See Survodutide: The Liver-Targeted Dual Agonist for MASH for a full analysis.
Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, has shown striking reductions in liver fat in phase 2 metabolic studies, with dedicated MASH trials ongoing. See Retatrutide and Liver Fibrosis: Triple Agonist Data for the current evidence.
The strategic question for the MASH treatment field is whether multi-agonist approaches that include glucagon receptor activation will prove superior to GLP-1 mono-agonism for liver-specific endpoints. Glucagon receptor activation increases hepatic fatty acid oxidation and energy expenditure, which could theoretically translate to greater liver fat reduction. The counter-argument is that semaglutide already has phase 3 data and FDA approval, while competitors remain in earlier development stages.
A related question is whether FGF21-based therapies will complement or compete with incretin approaches. FGF21 is a liver-derived hormone that regulates lipid metabolism and has shown liver fat reduction in early trials. See FGF21: The Metabolic Hormone from Your Liver for the evidence on this distinct mechanism.
Is Liver Fat Reduction Independent of Weight Loss?
One of the unresolved questions in semaglutide's hepatic pharmacology is whether it reduces liver fat through weight-loss-dependent or weight-loss-independent pathways. The distinction matters: if semaglutide's liver benefits derive entirely from caloric deficit and weight reduction, then any intervention producing equivalent weight loss should produce equivalent liver improvement. If direct hepatic mechanisms contribute, semaglutide may offer liver-specific advantages over diet, surgery, or other weight-loss drugs.
Several lines of evidence suggest weight-independent mechanisms are at work. In the phase 2 trial, subgroup analyses showed that NASH resolution rates on semaglutide exceeded what would be predicted by the magnitude of weight loss alone.[7] Patients who lost less than 5% body weight on semaglutide still showed higher NASH resolution rates than placebo patients who lost comparable weight.
The Jara et al. (2025) Nature Medicine study provides molecular support for this observation.[3] Semaglutide downregulated hepatic fibrosis-related gene pathways and reduced stellate cell activation markers in preclinical models, effects that occurred in parallel with but were not proportional to changes in body weight. The SLIM LIVER study's epigenetic analysis further suggests that semaglutide modifies biological aging markers in the liver, a process unlikely to be explained by caloric restriction alone.[11]
Post-hoc analysis by Armstrong et al. (2025) showed that semaglutide produced similar liver fat reductions regardless of baseline diabetes status, BMI category, or cardiometabolic risk profile.[8] This consistency across metabolic phenotypes supports the hypothesis that semaglutide's hepatic effects involve direct pathways rather than being mediated entirely through metabolic improvement.
The counterpoint is that no trial has been specifically designed to separate weight-dependent from weight-independent liver effects. Weight-matched comparisons between semaglutide and purely caloric-restriction arms would provide more definitive answers. Until such a trial exists, the contribution of direct hepatic mechanisms remains supported by circumstantial evidence rather than causal demonstration.
Safety Profile and Limitations
Semaglutide's safety profile in MASH trials is consistent with its known adverse event profile in obesity and diabetes. Gastrointestinal events are the most common: nausea (42% vs. 11% placebo at the 0.4 mg daily dose), constipation, vomiting, and diarrhea.[7] Most GI events are mild to moderate and decline over time as patients titrate to the target dose.
The phase 2 trial raised a signal for neoplasms. Malignant neoplasms were reported in 3 semaglutide patients (1%) versus 0 on placebo. Overall neoplasms (benign, malignant, or unspecified) occurred in 15% of semaglutide-treated patients versus 8% on placebo. No pattern in specific organ systems was identified, and the ESSENCE trial did not replicate this signal at a concerning rate. Post-marketing surveillance will continue to monitor this.
Rare cases of semaglutide-associated drug-induced liver injury have been reported.[18] These are idiosyncratic, unpredictable, and extremely uncommon, but they highlight that liver enzyme monitoring during treatment has value beyond measuring treatment response.
Several evidence gaps remain:
- Long-term clinical outcomes. The ESSENCE trial's part 2 will report on cirrhosis progression, liver transplant, and death. Until then, the assumption that histological improvement translates to clinical benefit rests on observational data showing that fibrosis stage predicts mortality.
- Durability after discontinuation. If patients stop semaglutide, does liver fat return? Weight regain after GLP-1 RA discontinuation is well documented; hepatic fat reaccumulation likely follows, though this has not been systematically studied in MASH populations.
- Cirrhosis. The Loomba 2023 data suggests semaglutide does not meaningfully improve F4 fibrosis. Patients with compensated cirrhosis remain without a clear incretin-based treatment option.
- Combination therapy. Whether semaglutide plus resmetirom offers additive or synergistic benefit is unknown. Both are now approved, and combination approaches will inevitably be tested.
- Weight-independent effects. Separating semaglutide's direct hepatic actions from its weight-loss-mediated benefits remains methodologically challenging. Some imaging studies show liver fat reduction that exceeds what would be predicted by weight loss alone, but this has not been definitively established in a trial designed to answer the question.
The Bottom Line
Semaglutide 2.4 mg weekly resolved MASH in 63% of patients and improved liver fibrosis in 37% in the 1,197-patient ESSENCE phase 3 trial, earning FDA approval in August 2025 for MASH with F2-F3 fibrosis. The evidence for MASH resolution is strong and consistent across phase 2, phase 3, and real-world studies. The fibrosis signal, while statistically significant in phase 3, is more modest, and semaglutide did not improve fibrosis in cirrhosis patients. Long-term outcomes data, durability after discontinuation, and optimal positioning relative to other MASH therapies (resmetirom, tirzepatide, survodutide, retatrutide) remain open questions that ongoing trials will address.